Nilotinib can override dasatinib resistance in chronic myeloid leukemia patients with secondary resistance to imatinib first-line therapy

被引：7
|
作者：
Breccia, Massimo
Cannella, Laura
Nanni, Mauro
Stefanizzi, Caterina
Alimena, Giuliana
机构：
[1] Univ Roma La Sapienza, Dept Human Biotechnol & Hematol, IT-00161 Rome, Italy
[2] Univ Roma La Sapienza, Dept Cell Biotechnol & Hematol, Rome, Italy
来源：
ACTA HAEMATOLOGICA | 2007年 / 118卷 / 03期
关键词：
D O I：
10.1159/000108639
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：162 / 164
页数：3
相关论文
共 50 条
  • [11] Cost-Utility Analysis of Dasatinib and Nilotinib in Patients With Chronic Myeloid Leukemia Refractory to First-Line Treatment With Imatinib in Thailand
    Kulpeng, Wantanee
    Sompitak, Sumalai
    Jootar, Saengsuree
    Chansung, Kanchana
    Teerawattananon, Yot
    CLINICAL THERAPEUTICS, 2014, 36 (04) : 534 - 543
  • [12] Comparative Safety and Health Care Expenditures Among Patients With Chronic Myeloid Leukemia Initiating First-Line Imatinib, Dasatinib, or Nilotinib
    Cole, Ashley L.
    Wood, William A., Jr.
    Muluneh, Benyam
    Lund, Jennifer L.
    Lafata, Jennifer Elston
    Dusetzina, Stacie B.
    JCO ONCOLOGY PRACTICE, 2020, 16 (05) : 243 - +
  • [13] Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia
    Gugliotta, Gabriele
    Castagnetti, Fausto
    Breccia, Massimo
    Gozzini, Antonella
    Usala, Emilio
    Carella, Angelo M.
    Rege-Cambrin, Giovanna
    Martino, Bruno
    Abruzzese, Elisabetta
    Albano, Francesco
    Stagno, Fabio
    Luciano, Luigia
    D'Adda, Mariella
    Bocchia, Monica
    Cavazzini, Francesco
    Tiribelli, Mario
    Lunghi, Monia
    Falcone, Antonietta Pia
    Musolino, Caterina
    Levato, Luciano
    Venturi, Claudia
    Soverini, Simona
    Cavo, Michele
    Alimena, Giuliana
    Pane, Fabrizio
    Martinelli, Giovanni
    Saglio, Giuseppe
    Rosti, Gianantonio
    Baccarani, Michele
    AMERICAN JOURNAL OF HEMATOLOGY, 2016, 91 (06) : 617 - 622
  • [14] First-line therapy of chronic myeloid leukemia - focus on dasatinib
    Amrein, Philip C.
    BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY, 2012, 2 : 77 - 85
  • [15] Immunoprofile of Patients with Chronic Myeloid Leukemia Treated with Imatinib, Nilotinib or Dasatinib
    Hayashi, Yoshiki
    Nakamae, Hirohisa
    Katayama, Takako
    Nakane, Takahiko
    Koh, Hideo
    Nishimoto, Mitsutaka
    Nakamae, Mika
    Yoshida, Masahiro
    Bingo, Masato
    Okamura, Hiroshi
    Aimoto, Mizuki
    Manabe, Masahiro
    Yoshimura, Takuro
    Inaba, Akiko
    Nanno, Satoshi
    Hagihara, Kiyoyuki
    Nakao, Yoshitaka
    Terada, Yoshiki
    Hino, Masayuki
    BLOOD, 2011, 118 (21) : 1607 - 1607
  • [16] COST EFFECTIVENESS OF NILOTINIB, DASATINIB AND IMATINIB AS FIRST LINE TREATMENT OF CHRONIC MYELOID LEUKEMIA IN COLOMBIA 2011
    Romero Martin, R. M.
    Alvis Nelson, A. N.
    De los Rios Magali, D. L. R. M.
    Chavez Diana, C. D.
    VALUE IN HEALTH, 2012, 15 (04) : A218 - A218
  • [17] THE RELATIVE VALUE OF DASATINIB VERSUS IMATINIB AS FIRST-LINE TREATMENT FOR CHRONIC MYELOID LEUKEMIA
    Betegon, L.
    Gilloteau, I
    Martin, P.
    Woolmore, A.
    Oyagueez, I
    VALUE IN HEALTH, 2012, 15 (07) : A420 - A420
  • [18] An indirect comparison between bosutinib, nilotinib and dasatinib in first-line chronic phase chronic myeloid leukemia
    Muresan, Bogdan
    Mamolo, Carla
    Cappelleri, Joseph C.
    Leip, Eric
    Viqueira, Andrea
    Heeg, Bart
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (05) : 801 - 809
  • [19] Comparison of Dasatinib, Nilotinib, and Imatinib in the Treatment of Chronic Myeloid Leukemia
    Ciarcia, Roberto
    Damiano, Sara
    Puzio, Maria Valeria
    Montagnaro, Serena
    Pagnini, Francesco
    Pacilio, Carmen
    Caparrotti, Giuseppe
    Bellan, Cristiana
    Garofano, Tiziana
    Polito, Maria Sole
    Giordano, Antonio
    Florio, Salvatore
    JOURNAL OF CELLULAR PHYSIOLOGY, 2016, 231 (03) : 680 - 687
  • [20] Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib for Patients with Chronic Myeloid Leukemia
    Miura, Masatomo
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2015, 38 (05) : 645 - 654
12345